RT Journal Article
SR Electronic
T1 A Randomized Trial of Otilimab in Severe COVID-19 Pneumonia (OSCAR)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.14.21255475
DO 10.1101/2021.04.14.21255475
A1 Patel, Jatin
A1 Beishuizen, Albertus
A1 Ruiz, Xavier Bocca
A1 Boughanmi, Hatem
A1 Cahn, Anthony
A1 Criner, Gerard J
A1 Davy, Katherine
A1 de-Miguel-Díez, Javier
A1 Fernandes, Sofia
A1 François, Bruno
A1 Gupta, Anubha
A1 Hanrott, Kate
A1 Hatlen, Timothy
A1 Inman, Dave
A1 Isaacs, John D
A1 Jarvis, Emily
A1 Kostina, Natalia
A1 Lacherade, Jean-Claude
A1 Martinez-Ayala, Pedro
A1 McEvoy, Charlene
A1 Muñoz-Bermúdez, Rosana
A1 Neisen, Jessica
A1 Plantefeve, Gaëtan
A1 Schifano, Lorrie
A1 Schwab, Lee
A1 Shahid, Zainab
A1 Shirano, Michinori
A1 Smith, Julia E.
A1 Sprinz, Eduardo
A1 Summers, Charlotte
A1 Terzi, Nicolas
A1 Tidswell, Mark A
A1 Williamson, Russell
A1 Wyncoll, Duncan
A1 Layton, Mark
YR 2021
UL http://medrxiv.org/content/early/2021/04/17/2021.04.14.21255475.abstract
AB BACKGROUND Increasing age is a risk factor for COVID-19 severity and mortality; emerging science implicates GM-CSF and dysregulated myeloid cell responses in the pathophysiology of severe COVID-19.METHODS We conducted a large, global, double-blind, randomized, placebo-controlled study evaluating a single 90 mg infusion of otilimab (human anti-GM-CSF monoclonal) plus standard of care in adults hospitalized with severe COVID-19 respiratory failure and systemic inflammation, stratified by age and clinical status. Primary outcome was the proportion of patients alive and free of respiratory failure at Day 28; secondary endpoints included all-cause mortality at Day 60.RESULTS Overall, 806 patients were randomized (1:1); 71% of patients receiving otilimab were alive and free of respiratory failure at Day 28 versus 67% receiving placebo, although this did not reach statistical significance (model-adjusted difference 5.3% [95% CI −0.8, 11.4]; p=0.09). However, there was a benefit in the pre-defined ≥70-year age group (model-adjusted difference 19.1% [95% CI 5.2, 33.1]; nominal p=0.009); these patients also had a reduction of 14.4% (95% CI 0.9, 27.9%; nominal p=0.04) in model-adjusted all-cause mortality at Day 60. Safety findings were comparable between otilimab and placebo, and consistent with severe COVID-19.CONCLUSIONS Although not statistically significant in the overall population, otilimab demonstrated a substantial benefit in patients aged ≥70, possibly reflecting a population that could benefit from therapeutic blocking of GM-CSF in severe COVID-19 where myeloid cell dysregulation is predominant. These findings are being confirmed in a further cohort of patients aged ≥70 in Part 2 of this study. (ClinicalTrials.gov number: NCT04376684).Competing Interest StatementJP, AC, KD, SF, AG, KH, DI, EJ, JN, LS, JES, RW and ML are employees and shareholders of GSK. AB, XBR, HB, GJC, JdMD, BF, TH, JDI, NK, JCL, PMA, CE, RM-B, GP, LE, ZS, MS, ES, CS and NT were investigators in the OSCAR trial, funded by GSK. MT and DW received a fee for serving on the IDMC for this study. BF reports consultancy fees with GSK, Enlivex, Inotrem, Takeda, Aridis, Transgene, AM-Pharma, Asahi-Kasai and Biomerieux within the last 36 months. RM-B has participated in an advisory board for GSK. JDI has received research funding from GSK, Janssen and Pfizer, and personal fees from AbbVie, Roche, UCB, and Janssen, all outside the submitted work. AB has received consultancy fees from GSK. CM has received research funding from the National Institutes of Health, US Department of Defense, Patient-Centered Outcomes Research Institute, GSK and AstraZeneca. GC has received research grants from ALung Technologies Inc, American College of Radiology, American Lung Associations, AstraZeneca, BioScale Inc, Boehringer Ingelheim, BREATH Therapeutics Inc, COPD Foundation, Coridea/ZIDAN, Corvus, Dr Karen Burns of St Michael's Hospital, Fisher & Paykel Healthcare Ltd, Galapagos NV, GSK, Kinevent, Lungpacer Medical Inc, National Heart Lung & Blood Institute, Nurvaira Inc, Patient-Centered Outcomes Research Institute, Pulmonary Fibrosis Foundation, PulmonX, Respironics Inc, Respivant Sciences, Spiration Inc, Steward St Elizabeth's Medical Center of Boston Inc and Veracyte Inc; and received personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, Broncus Medical, CSA Medical, EOLO Medical, Gala Therapeutics, GSK, Helios Medical, Ion, Merck, Medtronic, Mereo BioPharma, NGM Biopharmaceuticals, Novartis, Olympus, PulmonX, Respironics Inc, Respivant Sciences, The Implementation Group and Verona Pharma. JdMD LS, HB, J-CL, PMA, ZS, DW, CS, TH, GP, NT, MS, XBR, NK and ES have no other conflicts of interest to declare.Clinical TrialNCT04376684Funding StatementStudy funded by GSK. Medical writing support for manuscript development (in the form of editorial checks, figure development and assistance with submission) was provided by Clare Slater, PhD CMPP, and Leigh O Connor-Jones, PhD, of Fishawack Indicia Ltd. UK, part of Fishawack Health, and was funded by GSKAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the Declaration of Helsinki, Council for International Organizations of Medical Sciences International Ethical Guidelines, International Conference on Harmonization, Good Clinical Practice, and applicable country-specific regulatory requirements. The protocol was approved by relevant institutional review boards; the first IRB to approve the study was: Advarra Institutional Review Board, Suite 110, 6940 Columbia Gateway Drive, Columbia, Maryland, 21046, United StatesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGSK makes available anonymized individual participant data and associated documents from interventional clinical studies, which evaluate medicines upon approval of proposals submitted to www.clinicalstudydatarequest.com. To access original data for studies that have been re-analyzed, other types of GSK sponsored research, for study documents without patient-level data and for clinical studies not listed, please submit an enquiry via the website.